Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Small-cell lung cancer (SCLC) presents a poor prognosis, necessitating novel noninvasive biomarkers for monitoring therapeutic response.
• Current methods for assessing treatment efficacy in SCLC often lack real-time precision.

Discussion:

• This study utilized targeted error-correction sequencing on serial plasma samples and matched white blood cell DNA from 33 metastatic SCLC patients undergoing chemotherapy or immunotherapy.
• Circulating cell-free tumor DNA (ctDNA) levels, assessed through tumor-derived sequence alterations and plasma aneuploidy, were longitudinally monitored to evaluate molecular response.
• The combined analysis of ctDNA alterations and aneuploidy provided a comprehensive measure of cell-free tumor load (cfTL).

Key Insights:

• Molecular response, defined by ctDNA dynamics, accurately captured therapeutic effects and predicted long-term clinical outcomes, including overall and progression-free survival.
• Sustained elimination of cfTL indicated molecular response, correlating with significantly longer survival.
• Molecular responses were detected an average of 4 weeks earlier than radiographic imaging, offering a faster assessment of treatment efficacy.

Outlook:

• ctDNA analysis represents a precise method for early on-therapy molecular response assessment in SCLC.
• These findings have significant implications for real-time tumor burden monitoring and personalized treatment strategies in SCLC.
• Further development of ctDNA-based biomarkers could revolutionize SCLC patient management and clinical trial design.